A Real-World Multicenter Retrospective Study of Treatment Outcomes with Ipilimumab and Nivolumab in Mesothelioma

被引：0

作者：

Sridhar, A. ^{[1
]}

Schwecke, A. ^{[2
]}

Durer, S. ^{[3
]}

Hsu, M. L. ^{[4
,5
]}

Singh, A. ^{[1
]}

Mansfield, A. S. ^{[1
]}

Lou, Y. ^{[6
]}

Molina, J. R. ^{[1
]}

Leventakos, K. ^{[1
]}

Dimou, A. ^{[1
]}

Manochakian, R. ^{[7
]}

Shanshal, M. ^{[1
]}

Ernani, V. ^{[8
]}

Moffett, J. N. ^{[1
]}

Luce, A. ^{[2
]}

Parikh, K. ^{[2
]}

机构：

[1] Mayo Clin, Rochetser, MN USA

[2] Mayo Clin, Rochester, MN USA

[3] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Cleveland, OH USA

[4] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA

[5] Case Western Reserve Univ, Cleveland, OH USA

[6] Mayo Clin, Jacksonville, FL USA

[7] Mayo Clin, Rochester, FL USA

[8] Mayo Clin, Phoenix, AZ USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

DDR mutations; lung cancer; socioeconomic factors;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.14A.14

引用

页码：S278 / S278

页数：1

共 50 条

[1] Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study
Serra-Bellver, Patricio
Versluis, Judith M.
Oberoi, Honey K.
Zhou, Cong
Slattery, Timothy D.
Khan, Yasir
Patrinely, James R.
da Silva, Ines Pires
Martinez-Vila, C.
Cook, Natalie
Graham, Donna M.
Carlino, Matteo S.
Menzies, Alexander M.
Arance, Ana M.
Johnson, Douglas B.
Long, Georgina, V
Pickering, Lisa
Larkin, James M. G.
Blank, Christian U.
Lorigan, Paul
EUROPEAN JOURNAL OF CANCER, 2022, 176 : 121 - 132
[2] Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma
Dumoulin, D. W.
Douma, L. H.
Hofman, M. M.
van der Noort, V.
Cornelissen, R.
de Gooijer, C. J.
Burgers, J. A.
Aerts, J. G. J. V.
LUNG CANCER, 2024, 187
[3] Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan
Taniguchi, Tomoki
Iinuma, Koji
Kawada, Kei
Ishida, Takashi
Takagi, Kimiaki
Tomioka, Masayuki
Kawase, Makoto
Kawase, Kota
Nakane, Keita
Tobisawa, Yuki
Koie, Takuya
CURRENT ONCOLOGY, 2024, 31 (12) : 7914 - 7923
[4] Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM)
Enrico, Diego
Gomez, Juan Elias
Aguirre, Danilo
Tissera, Natalia Soledad
Tsou, Florencia
Pupareli, Carmen
Tanco, Delfina Peralta
Waisberg, Federico
Rodriguez, Andres
Rizzo, Manglio
Minatta, Nicolas
Rafael, Picon
Basbus, Luis
Lupinacci, Lorena
Kaen, Diego
Ramos, Mauro
Bluthgen, Virginia
Castagneris, Nicolas
Coppola, Maria Pia
Scocimarro, Alejandra
Guerra, Maria Florencia
Perfetti, Aldo
Levit, Patricio
Galvez-Nino, Marco
Mas, Luis
Rojas, Leonardo
Zuluaga, Jairo
Chacon, Matias
Corrales, Luis
Samtani, Suraj
Arrieta, Oscar
Cardona, Andres
Remon, Jordi
Martin, Claudio
CLINICAL LUNG CANCER, 2024, 25 (08)
[5] Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting
Shah, Rajiv
Reck, Martin
Grohe, Christian
Christoph, Daniel Christian
Buchmeier, Eva Lotte
Saalfeld, Felix Carl
Frost, Nikolaj
Kopp, Hans-Georg
Faehling, Martin
Griesinger, Frank
Roeper, Julia
Hoffknecht, Petra
Kuon, Jonas
Luan, Jingting
Chesi, Paolo
Christopoulos, Petros
Thomas, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
van Zeijl, M. C. T.
Wouters, M. W. J. M.
van den Eertwegh, A. J. M.
de Wreede, L. C.
Aarts, M. J. B.
van Akkooi, A. C. J.
Van den Berkmortel, F. W. P. J.
de Groot, J. W.
Boers-Sonderen, M. J.
van der Hoeven, J. J. M.
Hospers, G. A. P.
Kapiteijn, E.
Piersma, D.
van Rijn, R. S.
Suijkerbuijk, K. P. M.
Ten Tije, A. J.
Van der Veldt, A. A. M.
Vreugdenhil, G.
Haanen, J. B. A. G.
ANNALS OF ONCOLOGY, 2019, 30
[7] A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab
Brown, Landon Carter
Desai, Kunal
Kao, Chester
Kinsey, Emily Noelle
Healy, Patrick
Kephart, Julie
Harrison, Michael Roger
Ramalingam, Sundhar
Armstrong, Andrew J.
George, Daniel J.
Martin, Allison
Allman, Kimberly D.
Wood, Laura S.
Wei, Wei
Garcia, Jorge A.
Gilligan, Timothy D.
Gupta, Shilpa
Rini, Brian I.
Ornstein, Moshe Chaim
Zhang, Tian
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[8] Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment
Schmid, Sabine
Holer, Lisa
Gysel, Katrin
Koster, Kira-Lee
Rothschild, Sacha I.
Boos, Laura A.
Frehner, Lorenz
Almeida, Sabine Cardoso
Britschgi, Christian
Metaxas, Yannis
Mark, Michael
Froesch, Patrizia
Janthur, Wolf-Dieter
Allemann, Anna
Waibel, Christine
von der Muhll-schill, Catherine
Fruh, Martin
Mauti, Laetitia A.
JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (12):
[9] Nivolumab for Malignant Mesothelioma: A Real-World Experience
Niki, M.
Yokoi, T.
Takahashi, R.
Mikami, K.
Shibata, E.
Nakajima, Y.
Negi, Y.
Ishigaki, H.
Tada, A.
Higashiyama, T.
Kamei, T.
Minami, T.
Kuribayashi, K.
Kijima, T.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S758 - S758
[10] Real-World Evidence of Ipilimumab Plus Nivolumab Combination Therapy in Patients with Malignant Pleural Mesothelioma
Kondo, T.
Otsuki, T.
Kato, M.
Murata, T.
Mori, M.
Ota, H.
Wakita, H.
Kandori, T.
Kiyota, J.
Higashiyama, T.
Tokuda, M.
Tada, A.
Negi, Y.
Horio, D.
Fujimoto, D.
Mikami, K.
Takahashi, R.
Minami, T.
Kuribayashi, K.
Kijima, T.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S276 - S277

← 1 2 3 4 5 →